Dishman Carbogen Amcis' Q4 FY 2025-26 Quarterly Results

Result Summary

• Dishman Carbogen Amcis Ltd reported a 19.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 19.8%.
• Its expenses for the quarter were up by 11.4% QoQ and 19.8% YoY.
• The net profit decreased 267.6% QoQ and decreased 49.5% YoY.
• The earnings per share (EPS) of Dishman Carbogen Amcis Ltd stood at 1.39 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Dishman Carbogen Amcis Ltd operates in the pharmaceutical industry, focusing primarily on the development and production of active pharmaceutical ingredients (APIs) and drug intermediates. The company is renowned for its expertise in providing contract research and manufacturing services (CRAMS) to the pharmaceutical sector. With a global presence, Dishman Carbogen Amcis Ltd serves diverse clients, offering solutions that span from early-phase development to commercial production. The company is known for its strong research and development capabilities, aiming to deliver innovative and efficient solutions to its clients. As of now, specific recent developments or major announcements from the company are not available in the provided data.

Revenue

For the fourth quarter of the fiscal year 2026 (Q4FY26), Dishman Carbogen Amcis Ltd reported a total income of ₹867.82 crores. This represents a quarter-over-quarter (QoQ) increase of 19.5% from the ₹726.46 crores recorded in Q3FY26. On a year-over-year (YoY) basis, the total income increased by 19.8% compared to ₹724.31 crores in Q4FY25. The growth in revenue over both the quarter and year could indicate a positive trajectory in the company's sales performance. The increase in total income reflects the company's ability to generate higher sales or service revenue during this period.

Profitability

The profitability metrics of Dishman Carbogen Amcis Ltd for Q4FY26 show a mixed performance. The profit before tax for the quarter was ₹46.13 crores, showing a significant recovery from a loss of ₹10.44 crores in Q3FY26, which translates to a dramatic 541.9% QoQ increase. Compared to the profit before tax of ₹27.70 crores in Q4FY25, there was a 66.5% YoY increase. However, the profit after tax stood at ₹21.74 crores for Q4FY26, a substantial improvement from the loss of ₹12.97 crores in the previous quarter, but a decline of 49.5% YoY from the profit of ₹43.09 crores in Q4FY25. This decline in YoY profit after tax, despite the increase in revenue, suggests notable changes in the company's tax obligations or operational expenses.

Operating Metrics

The total expenses for Dishman Carbogen Amcis Ltd in Q4FY26 were ₹820.54 crores, representing an 11.4% increase QoQ from ₹736.90 crores in Q3FY26 and a 19.8% increase YoY from ₹684.86 crores in Q4FY25. The elevated expenses align with the increase in total income, which may indicate an expansion in operations or higher costs associated with scaling production. The earnings per share (EPS) for Q4FY26 was ₹1.39, a recovery from a negative EPS of ₹-0.83 in Q3FY26, yet a decrease of 49.5% from ₹2.75 in Q4FY25. These operating metrics highlight the company's current financial health and provide insights into its operational efficiency and cost management strategies.